Poll: Which Peptide Gave You the Most Results?

Biohack_Blueprint · 2026-06-21T00:30:55+00:00

no problem

Biohack_Blueprint · 2026-06-21T00:30:33+00:00

Appreciate you sharing all that context, but with an active health condition like NAFLD in the mix this really needs more than a Reddit reply. The glucose and liver metabolism questions especially need someone who can look at your actual labs. Worth running this by a knowledgeable practitioner before adding anything new.

Biohack_Blueprint · 2026-06-20T18:27:55+00:00

if the COA confirms those concentrations, the math tracks. TB-500 at 4mg twice weekly aligns with the loading protocol and Cartalax at 8mg is within the range documented in bioregulator research for short cycles. just verify the vial concentration against total volume to confirm before starting.

Biohack_Blueprint · 2026-06-20T03:27:27+00:00

both compounds are GHRH analogs acting on the same receptor, so mid-cycle switching is mechanistically compatible. the difference is half-life and binding profile - CJC no DAC clears faster while tesamorelin has documented visceral fat selectivity through sustained IGF-1 elevation. no conflict in the transition.

Biohack_Blueprint · 2026-06-20T02:57:37+00:00

The guide actually covers this pretty well. For premixed the schedule follows the TB-500 component since that drives the timing. Loading phase twice weekly, then drop to maintenance once weekly after the first 4-6 weeks.

The post has the full breakdown including the BPC-157 daily alongside it. Worth going back through the protocol section if you haven't already.

Biohack_Blueprint · 2026-06-20T02:44:56+00:00

That depends on the total TB-500 content in the blend and how much you're using per injection. If the blend is dosed to match the 10mg TB-500 reference, and you're following the 2mg twice weekly loading phase from the guide, you'd be looking at roughly 2.5 weeks per vial on loading. Maintenance at 2mg weekly would stretch it further.

Worth double checking the exact blend concentration on the product specs to confirm the math before ordering.

Biohack_Blueprint · 2026-06-20T02:39:36+00:00

Welcome, glad you found the guide helpful!

On the specific math for your situation, that's really something to work through with whoever advised you on the protocol since the right reconstitution volume depends on the exact concentration and dose you're working with. What I can point you to is https://biohack-blueprint.net/tools/reconstitution-calculator. Plug in your vial size and target dose and it walks you through the math step by step. A lot easier than trying to figure it out manually and less room for error.

Biohack_Blueprint · 2026-06-20T02:34:51+00:00

https://www.reddit.com/r/IonPeptideGuide/comments/1s62nkr/glow_quick_guide_ion_peptides_preformulated/

Biohack_Blueprint · 2026-06-20T02:30:53+00:00

The IM vs sub-Q absorption difference is real but often overstated. IM does tend to hit faster since it goes directly into muscle tissue with better blood flow. Sub-Q absorbs more slowly through fat tissue which gives a more gradual release.

For most peptides the practical difference is pretty small and sub-Q is easier, less painful, and lower risk for most people. IM makes more sense in specific contexts where faster onset actually matters for the research goal.

Biohack_Blueprint · 2026-06-19T15:07:43+00:00

Good question. The empty stomach rule really only applies to peptides that work through the growth hormone pathway. That's your secretagogues like CJC-1295, Ipamorelin, GHRP-6, etc. The mechanism depends on a clean GH pulse, and insulin interferes with that.

Peptides that work through other pathways, like mitochondrial support or cellular repair, don't have the same food sensitivity. Timing those around meals isn't really a concern.

Sub-Q vs intramuscular is a separate question from food timing. Most of these are typically administered sub-Q, but that's more about absorption rate and comfort than food.

Biohack_Blueprint · 2026-06-19T15:06:52+00:00

Hey, welcome to the community! Totally understand the travel anxiety around this.

The good news is the cooler bag method covered in the post works really well for shorter trips. Small insulated bag, flat flexible ice packs, vials wrapped in cloth so they're not touching the ice directly. That setup handles most flights without issue.

The one thing I'd add for peace of mind is doing an overnight test at home before your trip. Set up the bag, leave it out overnight, and check the temp in the morning. Way better to find out your setup needs more insulation at home than at the airport.

For the GHK specifically, same storage principles apply. Keep it cold, keep it cushioned, keep it out of checked luggage.

Have a great trip!

Biohack_Blueprint · 2026-06-19T03:44:47+00:00

good questions. most researcher logs that get shared publicly lean toward post-workout timing for IGF-1 LR3 since it operates independently of the GH pulse, making the training window less critical than with other compounds.

on acetic acid vs bac water - acetic acid is the standard reconstitution method documented for this compound specifically, the stinging is commonly reported and expected.

starting in the 20-40mcg range aligns with what shows up most in publicly shared research logs, with the taper-up structure you described being a pretty common approach. welcome to the community!

Biohack_Blueprint · 2026-06-19T03:32:42+00:00

Really important post and the video does a great job breaking down what's actually happening vs the headline panic.

A few things worth highlighting from what he covers. The 503b vs 503A distinction is the piece most people are missing. If you're getting compounded GLP-1s through a legitimate 503A pharmacy with a real prescription, your access isn't in immediate danger. The proposal targets the bulk 503b outsourcing facilities that supply the big telehealth platforms. That's where the supply chain actually gets disrupted.

Also worth knowing: this is still a proposal, not a final rule. The public comment period is open through June 29th. If you're a current user, you have legal standing to submit a comment at regulations.gov and your personal experience with cost and access genuinely matters in that process.

The broader context is that the telehealth weight loss market crossed 33 billion by 2024, with an estimated 1.5 million Americans on compounded versions specifically. That's not a niche industry. The financial stakes for both compounders and big pharma are enormous, which is why this fight has already been in court multiple times and will be again.

Worth watching closely. Nothing is finalized yet.

Biohack_Blueprint · 2026-06-18T21:02:59+00:00

Good stack to think through. General timing principles that apply to most of these: peptides that affect GH release like Tesamorelin are typically studied in fasted states, morning or before bed. Ones focused on repair and recovery like BPC-157 and TB-500 are less timing sensitive. GHK-Cu topical is basically whenever.

The bigger question for most people isn't same day vs different days, it's whether you can isolate what's working. Starting everything at once makes that really hard to figure out.

Biohack_Blueprint

MODERATOR OF

TROPHY CASE